HALO FY 2021 Earnings Report — Halozyme Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

Halozyme Therapeutics, Inc.HALO

FY 2021 Earnings

Reported February 22, 2022

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2021	Prior Q	FY 2020	QoQ Change	YoY Change
Revenue	$443M	—	$268M	—	65.7%
Op. Income	$276M	—	$144M	—	91.3%
Gross Margin	81.6%	—	83.8%	—	-2.2pp
Net Margin	90.8%	—	48.2%	—	42.6pp
EPS (Diluted)	$2.74	—	$0.91	—	201.1%
Free Cash Flow	$298M	—	$53M	—	462.8%

Revenue Flow

Item	Amount
REVENUE	$443M
Cost of Revenue	$81M
GROSS PROFIT	$362M
R&D Expenses	$36M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$50M
Other Expenses	$0
Operating Expenses	$86M
Cost & Expenses	$167M
OPERATING INCOME	$276M
Interest Income	$0
Interest Expense	$8M
Other Income/Expenses	-$27M
INCOME BEFORE TAX	$249M
Income Tax Expense	-$154M
Net Income from Continuing Ops	$403M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$403M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$403M
D&A	$3M
EBIT	$256M
EBITDA	$259M
EPS	$3
EPS Diluted	$3

Income Statement

Item	Amount
REVENUE	$443M
Cost of Revenue	$81M
GROSS PROFIT	$362M
R&D Expenses	$36M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$50M
Other Expenses	$0
Operating Expenses	$86M
Cost & Expenses	$167M
OPERATING INCOME	$276M
Interest Income	$0
Interest Expense	$8M
Other Income/Expenses	-$27M
INCOME BEFORE TAX	$249M
Income Tax Expense	-$154M
Net Income from Continuing Ops	$403M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$403M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$403M
D&A	$3M
EBIT	$256M
EBITDA	$259M
EPS	$3
EPS Diluted	$3

Cash Flow Statement

Item	Amount
Net Income	$403M
Depreciation & Amortization	$7M
Stock-Based Compensation	$21M
Deferred Income Tax	$0
Other Non-Cash Items	-$133M
Change in Working Capital	$3M
OPERATING CASH FLOW	$299M
Capital Expenditure	-$1M
Acquisitions (Net)	$0
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	-$405M
NET CASH FROM INVESTING	-$406M
Net Debt Issuance	$416M
Common Stock Repurchased	-$350M
Common Dividends Paid	$0
Other Financing Activities	$12M
NET CASH FROM FINANCING	$78M
FREE CASH FLOW	$298M
Net Change in Cash	-$29M

Balance Sheet

Item	Amount
Cash & Equivalents	$119M
Short-Term Investments	$622M
Net Receivables	$91M
Inventory	$54M
Other Current Assets	$0
TOTAL CURRENT ASSETS	$926M
PP&E (Net)	$9M
Goodwill	$0
Intangible Assets	$0
Long-Term Investments	$0
Tax Assets	$155M
Other Non-Current Assets	$14M
TOTAL NON-CURRENT ASSETS	$178M
TOTAL ASSETS	$1.1B
Account Payables	$2M
Short-Term Debt	$89M
Deferred Revenue	$2M
Other Current Liabilities	$0
TOTAL CURRENT LIABILITIES	$117M
Long-Term Debt	$787M
Deferred Revenue NC	$3M
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$544.0K
TOTAL NON-CURRENT LIABILITIES	$790M
TOTAL LIABILITIES	$907M
Common Stock	$138.0K
Additional Paid-In Capital	$256M
Retained Earnings	-$59M
Treasury Stock	$0
Accum. Other Comp. Income	-$620.0K
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$197M
Minority Interest	$0
TOTAL EQUITY	$197M
TOTAL LIABILITIES & EQUITY	$1.1B
Total Debt	$877M
Net Debt	$758M